VINC OTC
Vincerx Pharma, Inc.
1W: +0.0%
1M: +15.4%
3M: +18.1%
YTD: +15.4%
1Y: -72.2%
3Y: -99.9%
5Y: -100.0%
$0.01
+0.00 (+0.00%)
Weekly Expected Move ±3702.9%
$-1
$-1
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+100.0% ▲
Operating Income
-$31M
+26.2% ▲
Net Income
-$30M
+25.1% ▲
EPS (Diluted)
$-5.75
+15.9% ▲
EBITDA
-$31M
+19.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $173K | $340K | $939K | $915K | $0 |
| Gross Profit | -$173K | -$340K | -$939K | -$915K | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $7M | $40M | $52M | $28M | $15M |
| SG&A Expenses | $4M | $23M | $19M | $14M | $16M |
| Operating Expenses | $11M | $63M | $71M | $42M | $31M |
| Operating Income | -$11M | -$63M | -$69M | -$43M | -$31M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $8K | $0 | $0 | $0 | $0 |
| Income Before Tax | -$17M | -$39M | -$63M | -$40M | -$30M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$17M | -$39M | -$65M | -$40M | -$30M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-11.67 | $-8.30 | $-10.86 | $-6.84 | $-5.75 |
| EBITDA | -$16M | -$39M | -$62M | -$39M | -$31M |
| Shares Outstanding | 1M | 5M | 6M | 6M | 5M |